Top Ten most popular articles on Pharmafile.com this week
It's the end of the week, and the headlines were populated with stand-out stories that proved popular with our readers. Trump's nomination for the top role in the FDA had assuaged fears of partisanship by announcing he is to pull out of his previously existing interests in the pharma industry, while the EMA has raised concerns over 331 manufactured drugs, calling for them to be suspended. There has even been news of a newly researched drug to 'reverse' diabetes!
Check out the Top Ten most popular articles on Pharmafile.com this week!
Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it received a complete response letter (CRL) from the FDA.
Scott Gottlieb has voiced plans to sever his connections to the pharma industry to avoid any potential conflict of interest while serving as head of the FDA.
GSK has officially broken ground on the expansion of its site in County Durham. The expanded site will be an aseptic sterile facility that will make liquid biopharmaceuticals, located at its manufacturing base at Barnard Castle.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has called for the suspension of 331 drugs due to concerns over “misrepresentation of study data and deficiencies in documentation and data handling”.
A team of researchers have developed a drug therapy which has shown to ‘reverse’ the effects of diabetes in mice by restoring the body’s sensitivity to insulin, opening the door for potential new methods to rectify abnormal blood sugar levels.
Following on from the positive opinion given to Xeljanz in January of this year, Pfizer’s drug has now been given European Commission marketing authorisation for treatment of moderate to severe active rheumatoid arthritis (RA).
Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis and has a price that has the industry talking.
Eli Lilly’s latest press release indicated that it would be spending $850 million in developing its worldwide US operations, particularly in its diabetes manufacturing sites, in Indiana, in what can be seen as a pointed message to President Trump.
A rundown of five reasons to pay closer attention to the rise of fake medicines across the globe, including some hair-raising statistics on the danger of the medicine and the most commonly faked medicines in the world.
It looks like the once promising future for serelaxin may be in tatters, as it failed to impress in a Phase 3 trial to reduce cardiovascular death or worsening heart failure in patients with acute heart failure.